Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

2054 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Union Insurance Co., Ltd. Announces Appointments to Sustainable Committee
CI
Avistone Biotechnology Co. Ltd. Receives Approval from the National Medical Products Administration of China for Vebrelinib (APL-101) for the Treatment of Gliomas with Met Fusion Gene
CI
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
GL
Certain A Shares of Shanghai Urban Architecture Design Co., Ltd. are subject to a Lock-Up Agreement Ending on 20-APR-2024.
CI
China Vanke says it has plans in place amid short-term liquidity pressure
RE
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
Jiutian Chemical Group Limited Announces Retirement of Wu Yu Liang as Non-Executive and Lead Independent Director
CI
Property developer China Vanke plans to cut debt, boost cashflow
RE
Transcript : China Vanke Co., Ltd., 2023 Earnings Call, Mar 29, 2024
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
GL
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
AQ
Transcript : China Overseas Land & Investment Limited, 2023 Earnings Call, Mar 28, 2024
Certain A Shares of Shaanxi Sirui Advanced Materials Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-MAR-2024.
CI
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
GL
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
AQ
Jumbo Group Limited Announces Changes to its Board
CI
Shengjing Bank Co., Ltd. Announces Board Changes
CI
Certain A Shares of Zhejiang Chunhui Intelligent Control Co., Ltd. are subject to a Lock-Up Agreement Ending on 10-FEB-2024.
CI
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
GL
Certain A Shares of Zhejiang Taitan Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-JAN-2024.
CI
Beijing's support pledges scrape China stocks from lows, but scepticism high
RE
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
GL
Bridge dilemma captures divide over China in Taiwan elections
RE
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
GL
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
AQ
Shenzhen Changfang Group Co., Ltd. Announces Executive Appointments
CI
EHang’s Certified EH216-S Pilotless Passenger-Carrying Aerial Vehicles Debut Commercial Flight Demonstrations in Guangzhou and Hefei
GL
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
GL
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
AQ
Yield Go Holdings Ltd. Announces Board Appointments
CI
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
GL
Certain A Shares of Beijing Telesound Electronics Co., Ltd. are subject to a Lock-Up Agreement Ending on 25-NOV-2023.
CI
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
GL
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
AQ
NISUN INTERNATIONAL DEVELOPMENT : 21F, 55 LOUSHANGUAN RD CHANGNING DISTRICT, SHANGHAI, 200336 PEOPLE’S REPUBLIC OF CHINA PROXY STATEMENT AND NOTICE OF ANNUAL MEETING OF SHAREHOLDERS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 - Form 6-K
PU
Ubiqconn Technology, Inc. Establishes A Sustainable Development Committee
CI
China's Shenzhen state shareholders show liquidity support for Vanke
RE
China's Shenzhen state shareholders show liquidity support for Vanke
RE
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
GL
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
GL
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
GL
Funeng Oriental Equipment Technology Co., Ltd. Announces Directorate Elections
CI
Certain A Shares of Acter Technology Integration Group Co., Ltd. are subject to a Lock-Up Agreement Ending on 14-OCT-2023.
CI
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
AQ
Beijing Aerospace Shenzhou Intelligent Equipment Technology Co., Ltd. Announces Management Appointments
CI
Taiwan August export orders shrink for 12th month; growth seen returning in Q4
RE
Certain A Shares of Fujian Foxit Software Development Joint Stock Co., Ltd. are subject to a Lock-Up Agreement Ending on 8-SEP-2023.
CI
Quhuo International Hosts Ceremony for Shipment of New Energy Vehicles, Sending Off Nearly 3,000 Units
PR
China developer Vanke sees pressure on profit amid market downturn
RE
Transcript : China Vanke Co., Ltd., H1 2023 Earnings Call, Aug 31, 2023
No results for this search
  1. Stock Market
  2. Advanced search
  3. Liang Yu
  4. News